DEVELOPMENT OF NOVEL PDE4B INHIBITORS TO TREAT ALCOHOL USE DISORDER (SBIR PHASE II)

开发新型 PDE4B 抑制剂来治疗酒精使用障碍（SBIR II 期）

• 批准号: 10037802
• 负责人: JIMMY LU
• 金额: $ 99.88万
• 依托单位: CODEX BIOSOLUTIONS, INC.
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-09-23 至 2021-09-22
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10037802
• 关键词: Affect; Alcohol consumption; Alcoholism; American; Animals; Cells; Cessation of life; Contracts; Development; Drug Targeting; Emetics; Goals; In Vitro; Lead; Mus; PDE4B; Pharmaceutical Chemistry; Phase; Research; Small Business Innovation Research Grant; Testing; Toxic effect; Work; alcohol abuse therapy; alcohol use disorder; alcoholism therapy; base; improved; in vivo; inhibitor/antagonist; novel; novel drug class; novel therapeutics; pharmacokinetics and pharmacodynamics; preclinical study; preference; response; side effect

Excessive alcohol drinking is responsible for nearly 80,000 deaths per year in the U.S. and for the development of Alcohol Use Disorders (AUD) including alcoholism, which affects 18 million Americans. However, there are not many solutions for the treatment. Our recent research work indentified PDE4B as a promising target for the treatment of AUD. Selective PDE4B inhibitors could become a novel class of drugs for treatment of alcoholism given that PDE4B inhibitors may decrease ethanol intake and preference without causing emetic responses, the major side effects of pan PDE4 inhibitors.

在美国，过度饮酒每年造成近8万人死亡，并导致包括酒精中毒在内的酒精使用障碍（AUD）的发展，影响到1800万美国人。 然而，治疗的解决方案并不多。 我们最近的研究工作确定了PDE4B作为治疗AUD的有希望的靶点。 选择性PDE4B抑制剂可能成为一类新的治疗酒精中毒的药物，因为PDE4B抑制剂可以减少乙醇摄入量和偏好，而不会引起呕吐反应，这是泛PDE4抑制剂的主要副作用。